Xenetic Biosciences (NASDAQ:XBIO) and Diadexus (OTCMKTS:DDXSQ) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Earnings & Valuation
This table compares Xenetic Biosciences and Diadexus’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Xenetic Biosciences||$20,000.00||991.62||-$12.77 million||N/A||N/A|
This is a breakdown of recent ratings and price targets for Xenetic Biosciences and Diadexus, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Xenetic Biosciences currently has a consensus price target of $3.75, indicating a potential upside of 19.05%. Given Xenetic Biosciences’ higher possible upside, equities analysts clearly believe Xenetic Biosciences is more favorable than Diadexus.
This table compares Xenetic Biosciences and Diadexus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Xenetic Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Diadexus has a beta of -3.56, meaning that its share price is 456% less volatile than the S&P 500.
Insider and Institutional Ownership
3.2% of Xenetic Biosciences shares are held by institutional investors. 6.2% of Xenetic Biosciences shares are held by company insiders. Comparatively, 4.4% of Diadexus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Xenetic Biosciences beats Diadexus on 6 of the 8 factors compared between the two stocks.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Diadexus, Inc., a diagnostics company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company's PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure. The company markets its products to various national and regional clinical reference laboratories and hospitals in the United States, Europe, and internationally. The company is based in Poway, California. On June 13, 2016, Diadexus, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.